A report earlier this year suggested that four drugs are likely to be approved for fibromyalgia in the coming years. Recent reports suggest that one of those drugs - a very low dose, sublingual form of flexeril called Tonmya - is definitely on track.
Both Sleep and Pain Improved
Tonix - the developer of the drug - is moving fast. They reported that their Phase II clinical trial for Tonmya was filled in June of this year and reported results on the trial last month.They've already begun final (Phase III) trials.
[fright]
[/fright]A former study using EEG indicated the drug was increasing restorative sleep, which in turn was associated with reductions in pain, fatigue and depression. In a good sign for those in really severe pain, the most recent studies tied together pain levels and sleep quality; those FM patients in the most pain received the most improvements in sleep quality.
Dr. Lederman, Tonix CEO, emphasized that the drug is not a sleeping pill; it doesn't just knock you out - it improves sleep quality.
The drug fared quite well relative to the placebo - another sign that this drug may ultimately get approved.
“We also observed that the group treated with Tonmya was approximately twice as likely as placebo-treated patients to be in the top third of reported sleep quality improvement. Among all patients in BESTFIT who ranked highest in reported sleep quality improvement, twice as many Tonmya-treated patients experienced at least a 30% improvement in their pain as compared to those treated with placebo.” Dr. Lederman
Novel Approach
The drug's novelty involves the very low dose used and it's sublingual form. The drug is absorbed 10 times more effectively when delivered sublingually than when delivered orally.
[fleft]
[/fleft]Flexeril, the drug Tonmya is derived from, is only effective for a few weeks in reducing muscle spasms. Tonix discovered that cyclobenzaprine - the active ingredient in Flexeril - is converted into a metabolite called norcyclobenzaprine, which builds up in the body when the drug is taken orally. This problem is greatly reduced when the drug is taken sublingually.
The drug appears to be working by affecting down regulating activity in three different systems (serotonin (2A receptor), the sympathetic nervous system (alpha-1 adrenergic receptor) and histamine (histamine-1 receptor.)) The drug's unique approach suggests it's operating differently than any other FM drugs on the market - a good bit of news for FM patients looking for relief.
Tonix believes the drug is reducing both sympathetic nervous system and glutamate (a neuro-excitatory substance) activity. Because SNS functioning and glutamate activity may be increased in chronic fatigue syndrome (ME/CFS), the drug, if approved, will may present new options for ME/CFS patients as well. The drug is also currently being tested in PTSD and episodic tension type headaches.
CEO Lederman emphasized that Tomnya is not a sleeping pill; it's not designed to knock you out - it's designed to improve quality of sleep.
Final Trials Underway
Phase III trials are the last step before drug approval and they have already started. Tonix began a 500 person trials at 36 centers across the U.S. earlier this year. They expect to have the results back in the second half of 2016 and to get FDA approval in 2017.
If you're interested in being in the trial contact Jennifer Underwood at 267 536 3560 or jennifer.underwood@premier-research.com
_________________________________________________
The outcomes were presented via three posters at the 2015 Annual Meeting of the American College of Rheumatology / Association of Rheumatology Health Professionals.
Both Sleep and Pain Improved
“Our new analyses of the BESTFIT data show that those patients who reported the greatest improvement in sleep quality were the most likely to experience pain relief,” Seth Lederman, MD, Tonix CEO
Tonix - the developer of the drug - is moving fast. They reported that their Phase II clinical trial for Tonmya was filled in June of this year and reported results on the trial last month.They've already begun final (Phase III) trials.
[fright]
Dr. Lederman, Tonix CEO, emphasized that the drug is not a sleeping pill; it doesn't just knock you out - it improves sleep quality.
The drug fared quite well relative to the placebo - another sign that this drug may ultimately get approved.
“We also observed that the group treated with Tonmya was approximately twice as likely as placebo-treated patients to be in the top third of reported sleep quality improvement. Among all patients in BESTFIT who ranked highest in reported sleep quality improvement, twice as many Tonmya-treated patients experienced at least a 30% improvement in their pain as compared to those treated with placebo.” Dr. Lederman
Novel Approach
"The efficacy and tolerability profile of TNX-102 SL as demonstrated in prior clinical evaluations supports this candidate as a promising treatment for fibromyalgia." Daniel Clauw - FM researcher and Tonix consultant
The drug's novelty involves the very low dose used and it's sublingual form. The drug is absorbed 10 times more effectively when delivered sublingually than when delivered orally.
[fleft]
The drug appears to be working by affecting down regulating activity in three different systems (serotonin (2A receptor), the sympathetic nervous system (alpha-1 adrenergic receptor) and histamine (histamine-1 receptor.)) The drug's unique approach suggests it's operating differently than any other FM drugs on the market - a good bit of news for FM patients looking for relief.
Tonix believes the drug is reducing both sympathetic nervous system and glutamate (a neuro-excitatory substance) activity. Because SNS functioning and glutamate activity may be increased in chronic fatigue syndrome (ME/CFS), the drug, if approved, will may present new options for ME/CFS patients as well. The drug is also currently being tested in PTSD and episodic tension type headaches.
CEO Lederman emphasized that Tomnya is not a sleeping pill; it's not designed to knock you out - it's designed to improve quality of sleep.
Final Trials Underway
Phase III trials are the last step before drug approval and they have already started. Tonix began a 500 person trials at 36 centers across the U.S. earlier this year. They expect to have the results back in the second half of 2016 and to get FDA approval in 2017.
If you're interested in being in the trial contact Jennifer Underwood at 267 536 3560 or jennifer.underwood@premier-research.com
_________________________________________________
The outcomes were presented via three posters at the 2015 Annual Meeting of the American College of Rheumatology / Association of Rheumatology Health Professionals.
- “Relationship of Sleep Quality and Fibromyalgia Outcomes in a Phase 2b Randomized, Double-Blind, Placebo-Controlled Study of Bedtime, Rapidly Absorbed, Sublingual Cyclobenzaprine (TNX-102 SL).” (abstract no. 2307);
- “Responder Compared to Mean Change Analyses in a Fibromyalgia Phase 2b Clinical Study of Bedtime Rapidly Absorbed Sublingual Cyclobenzaprine (TNX-102 SL).” (abstract no. 2308); and
- “Bedtime, Rapidly Absorbed Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Fibromyalgia: Results of a Phase 2b Randomized, Double-Blind, Placebo-Controlled Study.” (abstract no. 2309).
Attachments
Last edited: